Status:
COMPLETED
Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment
Lead Sponsor:
Northwestern University
Collaborating Sponsors:
National Psoriasis Foundation
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Psoriasis
Eligibility:
All Genders
6-17 years
Brief Summary
This study will assess differences in inflammatory proteins, lipoprotein composition, cholesterol efflux and HDL-proteome in moderate-to-severe pediatric psoriasis who at baseline begin systemically a...
Eligibility Criteria
Inclusion
- Children ages 6-17 years of all races/ethnicities with plaque and/or extensive guttate psoriasis for at least 6 months and on topical or systemic therapy
- Patients in the systemic group can be starting a medication for the first time OR transitioning from another systemic if unresponsive and on that previous treatment for ≤ 3 months.
- Patients may concurrently have psoriatic arthritis if initiation of a systemic medication is warranted by skin severity.
- Children ages 6-17 years of all races/ethnicities with acne being treated with isotretinoin
- Children ages 6-17 years of all races/ethnicities without plaque or guttate psoriasis and history of severe acne or treatment with isotretinoin as controls.
Exclusion
- Patients less than 6 years of age or 18 years and older
- Patients with congenital heart disease, prior cardiac catheterizations/surgeries, or on cardiac medications in the past two years other than for hypertension (eg, calcium channel-blockers, beta-blockers and vasotropic medications).
- Patients who have other systemic inflammatory diseases (including atopic dermatitis, severe acne, inflammatory bowel disease, juvenile idiopathic arthritis, connective tissue diseases and/or other autoimmune diseases).
- Patients who have active infection or malignancy or have suffered from infection requiring oral or parenteral antibiotic in past 2 weeks.
- Patients and parents/caregivers unable to give written informed consent.
Key Trial Info
Start Date :
December 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 18 2025
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT03791216
Start Date
December 1 2018
End Date
June 18 2025
Last Update
July 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60611